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NITRIC oxide (NO), produced by alveolar macrophages
(AM) is used as a marker of respiratory tract inflam-
mation. Lipocortin 1 (Lc-1) is an anti-inflammatory,
glucocorticoid-inducible  protein.  The  current  aims
were to determine whether (a) an Lc-1-derived pep-
tide,  Ac2–26,  inhibited  lipopolysaccharide  (LPS)-
induced NO release by primary AM in vitro and (b) the
inhibitory action of dexamethasone was Lc-1-depend-
ent. LPS treatment stimulated NO release from rat AM.
Ac2–26 had little effect on unstimulated release, but
suppressed LPS-stimulated release at concentrations
‡ 320 nM (320 nM, 10 ± 3%; 3.2 m M, 15 ± 3%; 32 m M, 27
± 4% NO inhibited, mean ± SEM, n = 6). Inhibition by
dexamethasone  of  NO  release  was  unaffected  by
neutralizing anti-Lc-1 indicating that this action is Lc-
1-independent  in  primary  AM.  Nevertheless  inhibi-
tion of NO release by Ac2–26 (80 m M) was similar to
that  of  1 m M  dexamethasone  (Ac2–26,  40  ±  6%;
dexamethasone, 48 ± 6% NO inhibited, mean ± SEM,
n = 6).
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Introduction
Lipocortin-1  (Lc-1)  is  a  37kDa  anti-inflammatory,
glucocorticoid-inducible  member  of  the  annexin
superfamily of proteins. Its synthesis is upregulated
by  glucocorticoids  both  in  vitro and  in  vivo in  a
number of species, including man.1There is consider-
able evidence to suggest that intact Lc-1 and synthetic
peptides derived from its primary sequence possess
intrinsic  anti-inflammatory  properties  in a  range  of
experimental models.2–7
Lc-1 is a potential mediator of the anti-inflammatory
action of glucocorticoids. Increased levels of cellular
Lc-1 protein have been observed in vivo in human
alveolar  macrophages  (AM)  exposed  to  oral  gluco-
corticoid8 and in human mononuclear cells following
i.v.  administration  of hydrocortisone.9,10 Studies on
adrenalectomized rats have shown a decrease in Lc-1
mRNA  and  protein  in  the  lung,  spleen,  liver  and
kidney, suggesting not only a pharmacological mod-
ulation, but endogenous physiological steroidal con-
trol  on  Lc-1  expression  and  turnover.11 Immuno-
neutralization studies have confirmed that a number
of the anti-inflammatory actions of exogenous gluco-
corticoids are, in part,  dependent on Lc-1, both in
vivo
5–7,12 and in vitro.13–17
Previous studies have demonstrated that the lung is
a rich  source of Lc-118–20 which is detectable in a
number of different cell types, including human AM
21
and epithelial cells.22 Lc-1 is present in bronchoalveo-
lar lavage fluid,23 in which its levels are increased by
oral  glucocorticoids  in  healthy  volunteers,24,25
patients with lung disease,24 and control and carra-
geenin-treated rats.26 Increased Lc-1 concentrations in
lung  lavage  also  occur  in  response  to  non-specific
stimuli, such as cigarette smoke27 and LPS;28 this may
reflect increased expression of Lc-1, but may also be a
result of increased cell number, cell death or injury.
Inflammation in the respiratory tract is associated
with  the  release  of  numerous  inflammatory  media-
tors, including cytokines and eicosanoids. Recently,
nitric oxide (NO) has received much attention as a
potential  modulator  of lung  function in health  and
disease.  Both  constitutive  nitric  oxide  synthase
(cNOS) and inducible nitric oxide synthase (iNOS) are
present in the respiratory tract. The former is found in
endothelial cells and peripheral nerves, where it acts
as a smooth muscle relaxant and neurotransmitter29
and  the  latter,  which  is  probably  involved  in  lung
defence, is localized to AM and epithelial cells30,31 and
is increased in acute and chronic inflammation.32
Systemic administration of LPS or generalized sepsis
results in high levels of exhaled NO in the lungs of
rats.33 Wood smoke-exposed rats have elevated con-
centrations of NO metabolites in the plasma which
correlates with increased lung epithelial permeability,
a  process  reversible  with  NOS  inhibitors.34 This
suggests that smoke-induced damage may be due to
reactive nitrogen radicals in the lung. Intra-tracheal
instillation of LPS to rats also causes an increase in
epithelial leak, elevated levels of NO in respiratory
tract secretions and increased NO release by AM
35 and
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iNOS  activity  and  NO  release  also  occur  in  rat
macrophages  and  epithelial  cells  in  response  to
exposure to cytokines, such as IFN-g , TNFa and IL-1.31
Unlike cNOS, which produces NO at a constant low
level, activation of iNOS results in high output NO
production.
37 Thus,  many  pulmonary  inflammatory
conditions are accompanied by increased NO release.
Although it is unclear whether the NO is damaging or
protective, NO release is used as a marker of lung
inflammation.
Glucocorticoids inhibit NOS activity in the J774.2
macrophage-like cell line,38 an effect  which is Lc-1
dependent  in  these  cells.15 Similarly,  inhibition  by
glucocorticoid  of  LPS-induced  iNOS  activity  in  rat
lung homogenates is Lc-1-dependent, the AM being
suggested as a potential target for the glucocorticoid
action.15Therefore, we hypothesized that NO release
from  AM  in  vitro could  be  inhibited  by  gluco-
corticoids in a Lc-1-dependent manner. Primary AM
represent a useful in vitro model system for examin-
ing  the  relationship  between  glucocorticoids,  Lc-1
and  pulmonary  NO,  since  they  possess  functional
glucocorticoid receptors,39 release NO via the activity
of iNOS and express Lc-1.21 In addition they are the
predominant cell type in the airspaces with potential
anti-and  pro-inflammatory  functions. The AM  there-
fore encapsulates all the components under examina-
tion and, furthermore, is easily accessible and readily
isolated.
Thus  the  aims  of  the  current  study  were  to
determine the effect of a synthetic peptide derived
from the N-terminal of Lc-1 (Ac2–26),4,6,40,41 on NO
release by primary rat AM in vitro and to examine
whether inhibition of NO release by glucocorticoids
in this system is Lc-1 dependent.
Methods
Animals and removal of lungs
Pathogen-free male Wistar rats (Charles River), weigh-
ing 200–250g were killed by a lethal intra-peritoneal
injection of pentobarbitone (1g/kg body weight) and
heparin (1000U/kg body weight). Prior to excision,
the trachea was cannulated and the lungs perfused
free of blood via the right ventricle and pulmonary
artery using a gravity feed of sterile 0.15M NaCl.
Isolation and culture of alveolar macrophages
(AM)
Excised  lungs  were  fully  inflated  via  the  tracheal
cannula  with 10ml aliquots  of sterile  0.15M NaCl,
emptied,  and  lavage  repeated  until  approximately
50ml of fluid had been recovered. The lavage fluid
was pooled and centrifuged at 300 3 g for 10min at
4°C.  Pelleted  cells  were  resuspended  in  Hanks’s
balanced salt solution, without Ca2+ or Mg2+ (Sigma)
and centrifuged as before. BAL cells (approximately
95% AM) were resuspended in low protein hybridoma
medium, containing 2% foetal calf serum, glutamine
(2mM),  penicillin  (100U/ml)  and  streptomycin
(100m g/ml).  Cells  were  counted  and  seeded  in  to
96-well plates (Nunc) at a density of 1 3 105 cells per
well.  AM  were  allowed  to  adhere  for  3h  in  a
humidified chamber at 37°C in 5%  CO2 in air. All cell
culture reagents were obtained from Gibco.
Effect of dexamethasone and peptide Ac2–26 on
NO release
Following  the  3-h  adherence  period,  non-adherent
cells  and  conditioned  media  were  aspirated  and
replaced by fresh medium containing graded concen-
trations of Lc-1 peptide, Ac2–26 (3.2nM–80m M), or
dexamethasone  (10nM–1m M). Adherent  cells  were
pre-incubated  for  1h,  following  which  lipopoly-
saccharide  (0.1–10m g/ml,  serotype  055:B5  from
Escherichia coli, Sigma) was added to all wells except
controls and the cells incubated for a further 24h.
Conditioned media were harvested and analysed for
nitrite.  The  competitive  NOS  inhibitor  NG-mono-
methyl L-arginine (L-NMMA 4mM, Sigma) was added
to  selected  wells  to  determine  the  proportion  of
measured nitrite which originated from the activity of
NOS.
Effect of Lc-1 immuno-neutralization on
dexamethasone activity
Non-adherent  cells  and  conditioned  media  were
removed as above and replaced with fresh medium
containing a sheep polyclonal neutralising antibody to
Lc-1 (LC01, the generous gift of Professor R. J. Flower,
William Harvey Research Institute, London) used at
1:50 dilution. The cells were pre-treated with this anti-
serum for 3h, then incubated with graded doses of
dexamethasone for 1h and stimulated with lipopoly-
saccharide for 24h as described above.
Measurement of nitrite
Spontaneous oxidation of the NO radical in aqueous
solutions leads to the formation of nitrite (NO2–) as
the  predominant  stable  breakdown  product.29,42
Nitrite accumulation in conditioned media was there-
fore used as an index of NO release by AM, 24h post-
LPS. This was measured using the colorimetric Greiss
reaction.43 Nitrite  concentrations  were  determined
by  comparison  with  standard  solutions  of  sodium
nitrite (0.78–100m M) prepared in culture medium.
Data analysis
Data were analysed by the Wilcoxon’s signed rank test
for paired data; a probability of P<0.05 was regarded
as  statistically  significant.  Percentage  inhibition  of
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data in Figure 3 as:
% Inhibition
=
(LPS alone – LPS + Ac2–26)
(LPS alone – LPS + 4mML-NMMA)
3 100
Results
Effect of lipopolysaccharide on NO release
Median basal release of NO was 56, range 47–61nmol
NO/106 cells/24h in culture (Fig. 1, n = 4); 86%  was
inhibited by 4mM L-NMMA. Stimulation of AM with
LPS produced a concentration-dependent increase in
nitrite accumulation in the culture medium compara-
ble with that observed in previous studies31,38,44 (Fig.
1). At a concentration of 10m g LPS/ml, 85%  of NO
release  was  inhibited  by  L-NMMA.  Based  on  these
observations, an LPS dose range of 0.1–10m g/ml was
used in all subsequent experiments.
Effect of peptide Ac2–26 on NO release
The  peptide had no significant effect on basal NO
release in unstimulated cells  (Fig.  2) except at  the
highest concentrations of Ac2–26 tested (32m M and
80m M) where basal release was significantly inhibited
(31%   and  28%   respectively).  Ac2–26  significantly
inhibited LPS-induced NO release by AM at concentra-
tions  of  320nM  or  more  (Fig.  3).  The  maximum
inhibition observed was 40% by a concentration of
80m M Ac2–26. The  action  of Ac2–26  was  similar
irrespective of the LPS concentration used (Table 1)
and  therefore  only  data  for  LPS  at  10m g/ml  are
illustrated.
Inhibition of NO by a lipocortin peptide
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FIG. 1. Effect of  increasing  concentrations  of LPS  on  NO
release from rat AM in vitro. Data are presented as mean ±
SEM, n =  4;  Open  squares  represent  LPS-stimulated  NO
release; Open diamond represents basal (unstimulated) NO
release.
FIG. 2. Effect of Ac2–26 and dexamethasone on basal NO
release  by  rat  AM  in  vitro.  Percentage  NO  remaining
following  L-NMMA,  peptide  or  dexamethasone  treatment
was calculated using the following formula: (NO release by
unstimulated AM + peptide/NO release by unstimulated AM)
3 100 Data are presented as mean ± SEM, n = 6, *P < 0.05,
Wilcoxon’s signed rank test for paired data; open squares
represent  NO  release  in  the  presence  of  Ac2–26;  open
diamonds  represent  NO  release  in  the  presence  of  dex-
amethasone;  open  Circle  represents  NO  release  in  the
presence of L-NMMA.
FIG. 3. Effect of Ac2–26 and dexamethasone on NO release
by LPS-stimulated rat AM in vitro(10m g/ml LPS). Percentage
NO remaining following L-NMMA, peptide or dexametha-
sone treatment was calculated using the following formula:
(NO release by LPS-stimulated AM + peptide/NO release by
LPS-stimulated AM) 3 100 Data are presented as mean ±
SEM, n = 6, *P < 0.05, Wilcoxon signed rank test for paired
data; open squares represent NO release in the presence of
Ac2–26; open diamonds represent NO release in the pres-
ence of dexamethasone; open Circle represents NO release
in the presence of L-NMMA.Effect of dexamethasone on NO release
Dexamethasone  significantly  inhibited  basal  NO
release at all concentrations of drug and LPS-stimu-
lated  release  at  concentrations  above  10nM  dex-
amethasone  (Table  1  and  Figs  2  and  3).  Maximal
inhibition by dexamethasone was 48%.
Effect of anti-Lc-1 neutralizing antibody on NO
release
Pre-treatment of rat AM with a neutralizing antibody
to  Lc-1,  had  no effect  on  dexamethasone-mediated
inhibition of NO release, irrespective of the concen-
tration of dexamethasone used (Fig. 4).
Discussion
This study demonstrates that the N-terminal peptide
of Lc-1, Ac2–26, inhibits LPS-induced NO release from
rat AM in a concentration-dependent manner. To our
knowledge, this is the first such in vitro demonstra-
tion in a primary cell with a known pro-inflammatory
function. By increasing the dose of Ac2–26 to 80m M
it  was  possible  to  achieve  the  same  degree  of
inhibition as with 1m M dexamethasone. Interestingly
use of a neutralising anti-Lc-1 antiserum indicated that
the inhibitory action of dexamethasone itself on NO
release was independent of endogenous Lc-1.
Downregulation  of  LPS-induced NO  release  by  a
longer Lc-1 peptide, Lc-11–188, at a concentration of
20m g/ml has been reported in the J774.2 cell line.15
The observation that it was effective at a substantially
lower concentration than Ac2–26 may reflect differ-
ences between the responsiveness to Lc-1 of the cell
line and the primary AM used in the current study.
Another possibility is that the Ac2–26 was partially
degraded  by AM-derived  products  during  the  long
incubation period. Alternatively, there may be differ-
ences  between  the  peptides  themselves,  as  shown
previously  with  murine  neutrophils;4 it  is  possible
that the Ac2–26 does not activate the signal transduc-
tion machinery needed to trigger the cell response as
effectively as does the larger molecule. The optimal
size  for  inhibition  of  NO  release  by  Lc-1-derived
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Table 1. Effect of Ac2–26 and dexamethasone  on LPS-stimulated NO release. Data are presented as mean ± SEM, and
calculated as described in the legend to Fig. 3
LPS (m g/ml)
0 0.1 1 10
%  NO Remaining
Ac2–26 (m M)
0.0032 95 ± 5 100 ± 3 100 ± 2 100 ± 2
0.032 93 ± 7 99 ± 4 100 ± 3 95 ± 4
0.32 90 ± 7 94 ± 6 96 ± 3 92 ± 3*
3.2 88 ± 7 90 ± 6 95 ± 2 87 ± 3*
32 74 ± 9* 83 ± 6* 83 ± 6* 77 ± 4*
80 77 ± 8* 80 ± 7* 76 ± 6* 66 ± 6*
Dexamethasone (m M)
0.01 87 ± 3* 89 ± 1* 90 ± 2* 92 ± 5
0.1 71 ± 7* 73 ± 5* 79 ± 11 75 ± 10*
1 65 ± 10* 61 ± 5* 62 ± 5* 59 ± 6*
*P < 0.05, Wilcoxon signed rank test for paired data, n = 6.
FIG. 4. Effect of Lc-1 immunoneutralization on dexametha-
sone-mediated inhibition of NO release by LPS-stimulated
rat AM in vitro(10m g/ml LPS). Data are presented as mean ±
SEM, n = 6; open squares represent LPS-stimulated release
in  the  presence  of  dexamethasone  and  Lc-1  neutralizing
antibody  (1:50  dilution);  open  diamonds  represent  LPS-
stimulated  release  in  the  presence  of  dexamethasone
alone.peptides remains to be established. Provided that the
peptides are as effective as dexamethasone and low in
toxicity, the absolute concentration required to ach-
ieve inhibition is probably not a major consideration
for their use in vivo.
Dexamethasone was an effective inhibitor of NO
release by AM in this study, although interestingly, use
of neutralizing antiserum indicated that its action was
Lc-l-independent.  Pulmonary AM  treated  with  dex-
amethasone  are  capable  of  increasing  their  Lc-1
expression  and  release.21 However,  studies  in  our
laboratory indicate that at the highest concentration
of dexamethasone used in the current investigation
(1m M) the increase in cellular Lc-1 above baseline is
likely  to  be  modest  in  rat  AM.45 Since  the  anti-
inflammatory actions of glucocorticoids are mediated
via multiple pathways, the effect of dexamethasone
on NO release is likely to be via another mechanism,
perhaps  downregulation  of  iNOS.36 Similarly,  the
mode of action of dexamethasone in the lung in vivo
is not fully known. Previous publications by us and
others  have  demonstrated increases  in cellular  and
extracellular  pulmonary  Lc-1  following  oral  gluco-
corticoid24,25 and  also  after  non-specific  stimuli
including LPS15 and carrageenin.26 A previous study
in  vivo by  Wu  et  al.15 showed  that  neutralizing
antisera to Lc-1 blunted the action of dexamethasone
against LPS-induced NO release from lung  homoge-
nates, suggesting that increases in endogenous Lc-1
contribute to the steroid action. However, in vivo,
there are many other potential sources of Lc-1 in the
lung which may be targets for the dexamethasone,
such  as  epithelial  and  gland  cells.19 Our  previous
work  indicates  that  the  type  II  epithelial  cell  (TII)
releases enhanced levels of Lc-1 in response to lower
doses of dexamethasone than AM. Allied with their
high number in the lung,46–48 this makes TII likely
cellular  mediators  of  the  Lc-1-dependent  action  of
dexamethasone observed by Wu et al.15 Similarly, in
vivo, extracellular Lc-1 may inhibit NO release by a
variety of cell types not present in our simple in vitro
model.
In summary, we have shown that Ac2–26 causes
the  same  degree  of  inhibition  of  LPS-induced  NO
release  by AM  as  dexamethasone,  but  at  a  much
higher concentration and by a different mechanism.
This and other peptides derived from Lc-1 may have
therapeutic  potential for suppression of pulmonary
inflammation, since they could be delivered topically
to the target organ.
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